ES
ESLA.US Estrella Immunopharma Inc.
- Market cap
- USD 22.4M
- P/E
- -
- P/B
- 4.13x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ESLA.US undervalued?
Graham numberThe Graham number of Estrella Immunopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Estrella Immunopharma Inc. fundamental analysis
No fundamental analysis for Estrella Immunopharma Inc. yet.
Estrella Immunopharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lu…
Full company profileEstrella Immunopharma Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Estrella Immunopharma Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Operating Income | -734K | -1.69M | -11.1M | -7.31M | -8.85M | -13.1M | -8.75M |
| EBITDA | -734K | -1.69M | -11.1M | -7.31M | -8.85M | -13.1M | -8.75M |
| Net Income | -734K | -1.69M | -11.1M | -7.31M | -8.85M | -13.1M | -9.20M |
| EPS | -0.02 | -0.05 | -0.32 | -0.20 | -0.24 | -0.35 | -0.21 |
| Balance Sheet | |||||||
| Total Assets | 0.00 | 4.92M | 9.99M | 4.45M | 3.14M | 3.18M | 1.82M |
| Total Liabilities | 0.00 | 5.96M | 2.92M | 181K | 3.00M | 13.5M | 9.26M |
| Shareholders' Equity | 0.00 | -1.04M | 7.07M | 4.27M | 144K | -10.4M | -7.43M |
| Cash & Short-term Investments | 0.00 | 4.09M | 40.8K | 4.17M | 917K | 1.38M | 147K |
| Total Debt | - | - | 499K | - | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -671K | -1.44M | -1.04M | -16.1M | -3.11M | -1.79M | -17.0M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 |
| Free Cash Flow | -671K | -1.44M | -1.04M | -16.1M | -3.11M | -1.79M | -17.0M |
| Ratios | |||||||
| ROE | - | - | -157.2% | -171.1% | -6,155.7% | - | - |
| ROA | - | -34.2% | -111.3% | -164.2% | -281.7% | -411.2% | -504.0% |
| Debt to Equity | - | - | 0.07x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Estrella Immunopharma Inc. dividends
Estrella Immunopharma Inc. has not paid dividends in the last 6 fiscal years.
Who owns Estrella Immunopharma Inc.
- Insiders 60.42%
- Institutions 11.05%
- Public & others 28.53%
- Shares outstanding 43.5M
- Free float 38.2M
Top funds holding ESLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 269K | 0.62% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 80.3K | 0.18% | -0.21% | Sep 2026 |
| iShares Micro-Cap ETF | 45.1K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 26.2K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 16.8K | 0.04% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 5.50K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding ESLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 3.98M | 9.14% | -3.02% | Jun 2026 |
| Vanguard Capital Management, LLC | 417K | 0.96% | +8.99% | Jun 2026 |
| Geode Capital Management, LLC | 141K | 0.32% | -10.26% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 64.9K | 0.15% | 0.00% | Jun 2026 |
| BlackRock Inc | 52.0K | 0.12% | +30.44% | Jun 2026 |
| State Street Corp | 43.3K | 0.10% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 39.1K | 0.09% | -37.73% | Jun 2026 |
| Northern Trust Corp | 34.9K | 0.08% | +77.64% | Jun 2026 |
| U.S. Bancorp | 20.0K | 0.05% | +18.32% | Jun 2026 |
| Tower Research Capital LLC | 3.31K | 0.01% | -31.92% | Jun 2026 |
| UBS Group AG | 1.72K | 0.00% | -88.59% | Jun 2026 |
| The Toronto-Dominion Bank | 1.09K | 0.00% | 0.00% | Jun 2026 |
| Wolverine Asset Management LLC | 468.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 126.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
Estrella Immunopharma Inc. company profile
- Company name
- Estrella Immunopharma Inc.
- Ticker
- ESLA.US
- Exchange
- USA Stocks
- Listed since
- Sep 14, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 5858 Horton Street, EmeryVille, CA, United States, 94608
- Phone
- 510 318 9098
- Website
- estrellabio.com
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Estrella Immunopharma Inc. management
3- Dr. Cheng Liu Ph.D.Chief Scientific Officer, President & Director · born 1967
- Ms. Cynthia PussinenCEO & Chair of the Board · born 1969
- Mr. Jiandong XuChief Financial Officer · born 1971